7' APL relapse after previous arsenic therapy Pierre Fenaux (Paris)
3' Discussion
www.esh.org - info@esh.org 4
50' DEBATE – Best treatment for NPM1-mutated AML in the next future ?
Chair: Hervé Dombret (Paris)
15' Treatment of NPM1-mutated AML: Christoph Röllig (Dresden)
intensive standard treatment!
15' Targeted agents Ali Bazarbachi (Beyrouth)
20' Discussion
95' Allogeneic haematopoietic stem cell transplantation (HSCT)
Chair: Charles Craddock (Birmingham)
20' Case-based lecture : Jean-Hugues Dalle (Paris)
New GvHD prophylactic/curative treatment
20' Case-based lecture : Jorge Sierra (Barcelona)
Haplo-identical HSCT with acute leukaemia
20' Case-based lecture : Sergio Giralt (New York)
Prevention and treatment of VOD – 100 years after the “Senecio Disease”
Brief oral communication
5' Detectable minimal measurable disease by flow cytometry Claudia Núnez-Torrón Stock (Madrid)
before allogeneic transplantation is a factor of poor outcomes
in acute myeloid leukemia
30' Panel discussion
60' 3 Simultaneous Breakfast Meet the Expert Sessions
1. Therapy-related leukaemias Arnold Ganser (Hannover)
2. How I treat Ph+ ALL Oliver Ottmann (Cardiff)
3. How I treat older ALL Hervé Dombret (Paris)
95' Immunotherapy for acute leukaemia
Chair: Wendy Stock (Chicago)
20' Case-based lecture : Anita Rijneveld (Rotterdam)
Use of blinatumomab in ALL
20' Case-based lecture : Françoise Méchinaud (Paris)
CAR T-cells for precursor B-cell ALL